Viatris Inc. (NASDAQ: VTRS) is a Healthcare company (Drug Manufacturers - Specialty & Generic) with a market capitalization of $23.9B. The Maz Rating grades it against the other companies in its sector.
Viatris Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $20.82, Viatris Inc. trades at 1.6x sales and 1.7x book value, with an EV/EBITDA of 12.5. Over the last twelve months it generated about $14.7B of revenue and a net loss of $608M. It runs a gross margin of 35.2%, an operating margin of -0.5% and a net margin of -4.1%. It shows return on equity of -4.2%, return on invested capital of -0.3% and a free cash flow yield of 8.6%. On the balance sheet: a debt-to-equity ratio of 0.99 and a current ratio of 1.55. Over the past 52 weeks the share price ranged from $10.15 to $21.20, with a beta of 0.87.
Viatris Inc. pays a dividend yielding 2.31%. Its Maz Dividend Score is 1.70 out of 5, ranked against the other dividend payers in its sector (Safety 2.17, Growth 1.57, Yield 4.70, Consistency 1.98).
13 Wall Street analyst ratings cover the stock: 5 Buy, 7 Hold and 1 Sell, for a Hold consensus. This is the sell side's view, separate from the Maz Rating.
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Viatris Inc. (VTRS) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 64.3% / 30% · (Cash+Inv) / Mkt Cap (36m) 9.17% / 30% · Interest income / Revenue 0.00% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 64.3% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 9.17% / 33% · Receivables / Mkt Cap (36m) 16.5% / 49% · Interest income / Revenue 0.00% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 64.3% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 9.17% / 33.33% · Receivables / Mkt Cap (24m) 16.5% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 38.6% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 5.05% / 33.33% · Receivables / Avg Assets (4Q) 9.86% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 38.4% / 33.33% · (Cash+ST Inv) / Total Assets 5.48% / 33.33% · (Cash+Recv) / Total Assets 15.3% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
No. As of September 2026, Viatris Inc. (VTRS) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Viatris Inc. is over the AAOIFI limit on Debt / Mkt Cap (36m).
Viatris Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.